Kvinder i den fødedygtige alder skal anvende sikker kontraception under behandling og efter seponering af behandlingen, så længe mitotan kan detekteres i plasma.
Women of childbearing potential must use effective contraception during treatment and after discontinuation of treatment as long as mitotane plasma levels are detectable.